Organization | Universidade Federal de Santa Maria

Universidade Federal de Santa Maria Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Santa Maria Brazil (1960)

Organization Overview

First Clinical Trial

2009

NCT02128633

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Universidade Federal de Santa Maria

Active Ingredients

Drugs in Phase 4 Trials (6)

chlorhexidine (hibitane) (1 trial)

ketamine (ketalar) (1 trial)

lidocaine (xylocaine) (1 trial)

m. alternifolia oil (1 trial)

methadone (methadose) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 3 Trials (3)

leucovorin (1 trial)

potassium oxalate (1 trial)

sodium fluoride (18F) (1 trial)

Drugs in Other Trials (2)

Bixin (1 trial)

lycopene (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Cholecystolithiasis (Phase 4)

Cholelithiasis (Phase 4)

Coinfection (Phase 3)

Dental Plaque (Phase 4)

Dentin Sensitivity (Phase 3)

Gallstones (Phase 4)

Hypersensitivity (Phase 3)

Neuralgia (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 11